| Mirrabooka Investments Limited (MIR) ORDINARY FULLY PAID |
Financials |
$542 |
Weekly Estimated NTA as at 12 December 2025
|
15 Dec 2025 9:13AM |
$3.140 |
$2.420 |
fallen by
22.93%
|
|
| Light & Wonder Inc. (LNW) CHESS DEPOSITARY INTERESTS 1:1 |
Consumer Discretionary |
$10,217 |
Update - Notification of buy-back - LNW
|
15 Dec 2025 9:12AM |
$151.410 |
$124.510 |
fallen by
17.77%
|
|
| Pengana Capital Group Limited (PCG) ORDINARY FULLY PAID |
Financials |
$71 |
Monthly Funds Under Management - 30 November 2025
|
15 Dec 2025 9:12AM |
$0.660 |
$0.725 |
risen by
9.85%
|
|
PCG - Price-sensitive ASX Announcement
Full Release
Key Points
- Pengana Capital Group Limited (ASX: PCG) reported funds under management (FUM) as of 30 November 2025 at $3,856.48 million.
- The FUM increased from $3,840.24 million at 31 October 2025.
- The announcement was approved by Paula Ferrao, Company Secretary.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aristocrat Leisure Limited (ALL) ORDINARY FULLY PAID |
Consumer Discretionary |
$34,043 |
2025 Annual Report and date of 2026 Annual General Meeting
|
15 Dec 2025 9:12AM |
$56.710 |
$56.570 |
fallen by
0.25%
|
|
| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$280 |
Update - Notification of buy-back - AMH
|
15 Dec 2025 9:12AM |
$1.035 |
$0.890 |
fallen by
14.01%
|
|
| Mt Malcolm Mines NL (M2M) ORDINARY FULLY PAID |
Materials |
$6 |
M2M Secures 500k TPA Processing Mill
|
15 Dec 2025 9:12AM |
$0.012 |
$0.008 |
fallen by
33.33%
|
|
M2M - Price-sensitive ASX Announcement
Full Release
Key Points
- Mt Malcolm Mines NL (M2M) has secured a 500,000 tpa carbon-in-leach (CIL) gold processing plant.
- The plant components were acquired from Absolute West Pty Ltd for $550,000 plus GST.
- A deposit of $100,000 is payable on execution, with the balance in two instalments upon delivery.
- The acquisition includes major components like crushing, milling, power, pumps, coarse gold circuit, and elution extraction.
- This positions M2M as one of few juniors with such processing capabilities in a prolific gold region.
- The plant is relocation-ready and can be operational within 12–15 months after the final investment decision.
- The acquisition enables future self-processing and generates cash flow through toll-milling.
- M2M aims to become a self-sufficient gold producer in Leonora, where processing capacity is limited.
- Discussions are underway for a feasibility study on developing a fully functional processing facility.
- A detailed relocation, refurbishment, and commissioning plan will be announced in upcoming months.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kip McGrath Education Centres Limited (KME) ORDINARY FULLY PAID |
Consumer Discretionary |
$22 |
Update - Notification of buy-back - KME
|
15 Dec 2025 9:12AM |
$0.570 |
$0.410 |
fallen by
28.07%
|
|
| Morphic Ethical Equities Fund Limited (MEC) ORDINARY FULLY PAID |
Financials |
$41 |
Update - Notification of buy-back - MEC
|
15 Dec 2025 9:11AM |
$1.165 |
$1.350 |
risen by
15.88%
|
|
| Connexion Mobility Ltd (CXZ) ORDINARY FULLY PAID |
Information Technology |
$17 |
Update - Notification of buy-back - CXZ
|
15 Dec 2025 9:11AM |
$0.026 |
$0.024 |
fallen by
7.69%
|
|
| EV Resources Limited (EVR) ORDINARY FULLY PAID |
Materials |
$21 |
Maiden Drilling Set to Commence at Los Lirios Project
|
15 Dec 2025 9:11AM |
$0.009 |
$0.007 |
fallen by
22.22%
|
|
EVR - Price-sensitive ASX Announcement
Full Release
Key Points
- Maiden drill program to commence in early January 2026.
- Fully funded program targeting high-grade antimony under historical workings.
- Phase 1 comprises 1,500-2,000 meters of diamond drilling.
- Aim to deliver maiden JORC resource by Q3 2026.
- Parallel advancement at Los Lirios and Tecomatlán Plant for production readiness.
- Part of a larger 2026 exploration campaign to unlock full scale potential.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Prescient Therapeutics Limited (PTX) ORDINARY FULLY PAID |
Health Care |
$68 |
PTX secures EU Authorisation to commence PTX-100 Trial
|
15 Dec 2025 9:10AM |
$0.089 |
$0.065 |
fallen by
26.97%
|
|
PTX - Price-sensitive ASX Announcement
Full Release
Key Points
- Prescient Therapeutics Limited secures EU authorisation to commence the PTX-100 trial.
- The trial targets patients with relapsed/refractory Cutaneous T-cell Lymphoma (CTCL) in Italy.
- PTX-100 is a first-in-class therapy targeting cancer growth pathways.
- The trial is advancing into Phase 2a with recruitment beginning in Europe.
- The European Clinical Trials Information System (CTIS) granted the authorisation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clime Capital Limited (CAM) ORDINARY FULLY PAID |
Financials |
$97 |
Update - Notification of buy-back - CAM
|
15 Dec 2025 9:10AM |
$0.690 |
$0.690 |
fallen by
0%
|
|
| Cynata Therapeutics Limited (CYP) ORDINARY FULLY PAID |
Health Care |
$4 |
Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial
|
15 Dec 2025 9:09AM |
$0.265 |
$0.016 |
fallen by
93.96%
|
|
CYP - Price-sensitive ASX Announcement
Full Release
Key Points
- Patient enrolment completed for Phase 2 aGvHD clinical trial.
- 65 participants enrolled across the USA, Europe, and Australia.
- Participants received either steroids plus CYP-001 or steroids plus placebo.
- Primary evaluation period to conclude in March 2026, results expected by June 2026.
- CYP-001 is designed to improve response rates and survival in aGvHD.
- Phase 1 trial showed 87% overall response and no serious adverse events.
- CYP-001 has Orphan Drug Designation by the US FDA for aGvHD treatment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Light & Wonder Inc. (LNW) CHESS DEPOSITARY INTERESTS 1:1 |
Consumer Discretionary |
$10,217 |
LNW Form 3-Amendment (Fine Capital)
|
15 Dec 2025 9:09AM |
$151.410 |
$124.510 |
fallen by
17.77%
|
|
| Intelligent Monitoring Group Limited (IMB) ORDINARY FULLY PAID |
Industrials |
$237 |
Trading Halt
|
15 Dec 2025 9:08AM |
$0.640 |
$0.575 |
fallen by
10.16%
|
|
IMB - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt requested by Intelligent Monitoring Group Limited.
- Pending announcement regarding proposed equity raising.
- Halt effective from 15 December 2025.
- Trading expected to resume on 17 December 2025 or upon announcement.
- No known reasons to deny the trading halt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nova Minerals Limited (NVA) CHESS DEPOSITARY INTERESTS 12:1 |
Materials |
$133 |
Suspension from Quotation
|
15 Dec 2025 9:08AM |
$1.030 |
$0.600 |
fallen by
41.75%
|
|
NVA - Price-sensitive ASX Announcement
Full Release
Key Points
- Nova Minerals Limited requests voluntary suspension of its securities.
- The suspension is under ASX Listing Rule 17.2.
- Suspension is due to pending announcement on proposed capital raising.
- Trading halt was requested prior on 11 December 2025.
- Expected end of suspension on 17 December 2025.
- No known impediments to granting the suspension.
- Request authorized by the Executive Directors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Meridian Energy Limited (MEZ) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Utilities |
$6,257 |
Financial assistance in connection with FY26 Equity Plan
|
15 Dec 2025 9:08AM |
$4.800 |
$4.750 |
fallen by
1.04%
|
|
| Brazilian Rare Earths Limited (BRE) ORDINARY FULLY PAID |
Materials |
$1,401 |
Amargosa Bauxite Presentation
|
15 Dec 2025 9:08AM |
$4.000 |
$5.000 |
risen by
25%
|
|
| Light & Wonder Inc. (LNW) CHESS DEPOSITARY INTERESTS 1:1 |
Consumer Discretionary |
$10,217 |
LNW Form 4-Amendment (Fine Capital)
|
15 Dec 2025 9:07AM |
$151.410 |
$124.510 |
fallen by
17.77%
|
|
| BKI Investment Company Limited (BKI) ORDINARY FULLY PAID |
Financials |
$1,441 |
BKI 12 December 2025 Weekly NTA
|
15 Dec 2025 9:06AM |
$1.705 |
$1.785 |
risen by
4.69%
|
|
| Epiminder Limited (EPI) ORDINARY FULLY PAID |
Health Care |
$61 |
Change of Director's Interest Notice DO
|
15 Dec 2025 9:06AM |
$1.150 |
$0.350 |
fallen by
69.57%
|
|
| Orthocell Limited (OCC) ORDINARY FULLY PAID |
Health Care |
$208 |
Remplir Regulatory Application for US$750m EU-UK Market
|
15 Dec 2025 9:05AM |
$1.020 |
$0.765 |
fallen by
25%
|
|
OCC - Price-sensitive ASX Announcement
Full Release
Key Points
- Orthocell submits regulatory application to BSI for EU and UK markets.
- The EU and UK nerve repair market represents a US$750 million opportunity.
- Application supported by 81.1% treatment success rate in real-world evidence study.
- Expected 'CE' and 'UKCA' certification by 3Q CY26.
- Orthocell has a strong balance sheet with approximately $50 million in cash.
- Orthocell plans to utilize in-country distributors and key opinion leaders for market strategy.
- Remplir already approved in various countries including the US, Australia, and Hong Kong.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$1,575 |
FDA approves DAYBUE STIX (trofinetide), powder formulation
|
15 Dec 2025 9:05AM |
$19.010 |
$12.420 |
fallen by
34.67%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- FDA approved DAYBUE STIX, a new powder formulation of trofinetide.
- DAYBUE STIX is designed for Rett syndrome patients aged two years and older.
- The new formulation offers flexible dosing options by mixing with liquids.
- Neuren Pharmaceuticals will receive royalties from the sales.
- Approval was based on bioequivalence with the original DAYBUE oral solution.
- DAYBUE STIX expected to be available in early 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$177 |
CFO transition
|
15 Dec 2025 9:04AM |
$0.200 |
$0.170 |
fallen by
15%
|
|
| Great Southern Mining Limited (GSN) ORDINARY FULLY PAID |
Materials |
$22 |
EMERGING DISCOVERY AT AMY CLARKE
|
15 Dec 2025 9:04AM |
$0.029 |
$0.019 |
fallen by
34.48%
|
|
GSN - Price-sensitive ASX Announcement
Full Release
Key Points
- Great Southern Mining Limited (GSN) is actively involved in exploration activities through its subsidiary East Laverton Exploration Pty Ltd.
- The Amy Clarke prospect is part of the Duketon Greenstone Belt, featuring significant geological structures conducive to gold mineralization.
- Recent drilling at the Amy Clarke prospect includes several drill holes with notable gold intersections.
- The exploration methods involve air-core drilling and sampling, with intervals showing gold assay results above 0.2 g/t Au.
- Future exploration efforts will focus on assessing recent drill results to further understand the mineralization at Amy Clarke.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.